Associations between early tumor shrinkage/depth of response and survival from the ARCAD database.

JNCI Cancer Spectr · 2025 · PMC12159729 · PMID 40280867

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, in early tumor shrinkage–negative patients on bevacizumab-based therapy showed a trend toward better overall survival, PFS, and postprogression survival outcomes compared with patients on anti-EGFR–based therapy (overall survival, HR = 1.22 [95% CI = 1.00 to 1.48]; PFS, HR = 1.27 [95% CI = 1.05 to 1.53]; postprogression survival, HR = 1.13 [95% CI = 0.90 to 1.43]).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.